1.. Introduction {#s1}
================

Angiogenesis is essential for normal embryonic development, yet is central to postnatal human diseases such as retinopathies and cancer. During embryonic development, early vascular formation must precede onset of cardiac contraction, and hence vasculogenesis (formation of the axial vessels by migration of mesodermal angioblasts) occurs prior to, and independent of, blood flow. However, the contribution of blood flow to subsequent patterning of the vasculature by angiogenesis is less clear.

The zebrafish is an outstanding model of vertebrate angiogenesis due to optical clarity and a range of transgenic lines allowing *in vivo* visualization of cellular behaviour. Strikingly, the embryo is not dependent upon a circulation for oxygenation, as it obtains sufficient via diffusion from the incubating medium until several days old.^[@CVT170C1]^ Thus, the zebrafish embryo heart can be stopped without inducing hypoxia, allowing the discrimination of the effects of blood flow without the confounding influence of ischaemia.^[@CVT170C2]^ This makes it well suited to examining the effect of blood flow on vascular development.

We previously showed that during zebrafish development, formation of the paired intersegmental vessels (ISVs) running between the somites from the aorta occurs in the absence of blood flow.^[@CVT170C3]^ This suggests that initiation of ISV formation is blood flow independent, although a recent study suggests blood flow contributes to the anastomosis of ISVs to form the dorsal longitudinal anastomotic vessel (DLAV).^[@CVT170C4]^ In contrast with ISV formation, development of other vessels in the zebrafish does require blood flow, such as the accessory fifth aortic arch (AA5x).^[@CVT170C5]^ We previously showed blood flow negatively regulates endothelial expression of the chemokine receptor CXCR4a.^[@CVT170C3]^ CXCR4a is required for hindbrain vascularization (but not ISV formation)^[@CVT170C6]^ by stabilizing angiogenesis.^[@CVT170C7]^ It is unknown why development of the AA5x and hindbrain vasculature, but not ISVs, requires blood flow.

In contrast with these studies that have shown blood flow is either dispensable or necessary for vessel formation, other reports have shown a more inhibitory effect of blood flow on vascular formation. Shear stress has been shown to inhibit sprouting angiogenesis either *in vitro*^[@CVT170C8]^ or *in vivo*.^[@CVT170C9]^ Clearly, much remains to be understood how the physical forces exerted by blood flow integrate with molecular mechanisms to influence angiogenesis.

Notch signalling refers to a range of cell--cell interactions where Notch ligands, such as the delta-like ligands (*dll1-4*) and jaggeds (*jag1&2*) interact with Notch receptors on neighbouring cells to induce alterations in gene expression and cellular phenotype.^[@CVT170C10]^ These effects are predominantly mediated via the transcription factor CSL. Notch signalling plays a central role in vascular development and angiogenesis.^[@CVT170C10]^ Although Notch signalling is required for vasculogenesis and axial vessel formation,^[@CVT170C11]^ during later developmental angiogenesis Notch signalling plays an inhibitory role. For example, during ISV formation, endothelial tip cells express the Notch ligand *dll4*, which induces Notch signalling in adjacent endothelial stalk cells. Loss of function of *dll4* leads to excessive and aberrant angiogenesis^[@CVT170C12]^ including of the ISVs in zebrafish.^[@CVT170C13]^

To identify mechanisms whereby blood flow might regulate angiogenesis, we examined whether blood flow influences Notch signalling in the developing zebrafish vasculature. We find that in the absence of blood flow the Notch ligand *dll4* is up-regulated in the zebrafish vasculature, leading to increased Notch signalling. However, as previously demonstrated, the absence of blood flow does not affect ISV patterning in wild-type embryos, suggesting the up-regulation of Notch signalling is insufficient to perturb normal developmental angiogenesis of the ISV. We therefore examined ISV formation in zebrafish with constitutively up-regulated hypoxic signalling due to homozygous mutation in the von Hippel Lindau protein gene *vhl*.^[@CVT170C14]^ We find these embryos display abnormal and excessive ISV angiogenesis that is completely abolished in the absence of blood flow, whereas normal ISV patterning is preserved. Thus, our data reinforce the suggestion that the contribution of blood flow to angiogenesis is highly context dependent, and that blood flow is required in the clinically important context of angiogenesis driven by hypoxic signalling.

2.. Methods {#s2}
===========

2.1. Fish strains {#s2a}
-----------------

Studies were performed under Home Office licence 40/3434 and conformed to Directive 2010/63/EU of the European Parliament. The vhl^hu2117^ mutant was previously described.^[@CVT170C14]^ This was crossed with the following transgenic lines: *Tg(fli:eGFP)*,^[@CVT170C15]^ kindly supplied by Brant Weinstein, *Tg(flk1:EGFP-nls)*^[@CVT170C16]^ kindly supplied by Markus Affolter, and *Tg(kdrl:HRAS-mCherry)^s916^*^[@CVT170C17]^ kindly supplied by Arndt Siekmann. The *Tg(CSL-venus)qmc61*transgenic line was generated by co-author Gering\'s group.

2.2. Morpholino knockdown {#s2b}
-------------------------

Morpholino antisense oligonucleotide (Gene Tools, Oregon USA) were diluted in phenol red (Sigma UK) 0.5% solution and injected into the yolk of a 1--4 cell embryo at a dose of 4.2 ng. Morpholino sequences were: *tnnt2* (ATG/start) blocking morpholino 5′CATGTTTGCTCTGACTTGACACGCA3′ as published,^[@CVT170C18]^ Control morpholino 5′CCTCTTACCTCAGTTACAATTTATA 3′ (Gene Tools stock control), and *dll4* (ATG/start) blocking morpholino: 5′-GAGAAAGGTGAGCCAAGCTGCCATG-3′ as published.^[@CVT170C19]^

2.3. Drug treatments {#s2c}
--------------------

The myosin ATPase inhibitor 2,3-butanedione 2-monoxime (BDM) (Sigma UK) was used to block cardiac contraction in the developing embryo as previously published.^[@CVT170C20]^ This was dissolved at \[15 mM\] in E3 embryo media and added after established embryonic circulation at 36 h post-fertilization (hpf) until imaging at 3 dpf.

2.4. Reverse transcription--quantitative polymerase chain reaction {#s2d}
------------------------------------------------------------------

RNA was extracted from the dissected trunk and tail segments of groups of 30 pooled 48 hpf embryos. RNA was isolated immediately using Trizol (Sigma, UK) and then chloroform extracted and subsequently precipitated. cDNA was synthesized from the purified RNA using the Verso cDNA reverse transcription kit (Thermo Scientific, UK). Reverse transcription--quantitative polymerase chain reaction (RT--qPCR) was performed using iQ SYBR green supermix with a My iQ cycler (BioRad USA). Primers: β-actin forward (5′-GCAGAAGGAGATCACATCCCTGGC-3′), B-actin reverse (5′-CATTGCCGTCACCTTCACCGTTC-3′), cxcr4a forward (5′-TTGTGCTCACTCTGCCATTC-3′), cxcr4a reverse (5′-ACCGGTCCAAACTGATGAAG-3′), dll4 forward (5′- GCTTGGCTCACCTTTCTCAT-3′), dll4 reverse (5′-CGGAAGAAAGTCCTGCAGTC-3′), Nrarpa forward (5′-AGCTGCTTCGGACTCGTTAC-3′), Nrarpa reverse (5′-CGAGGTAGCTGATGCAGAGA-3′), Notch 3 forward (5′- CGGCCTGGTTATATTGGTTC-3′), Notch 3 reverse (5′-TCTAAAGCCTCGCTGACACA-3′), her12 forward (5′-GCTGAGGAAGCCGATAGTTG-3′), her12 reverse (5′-GCGAGAGGAAGTGGACAGAC-3′), ephrin B2 forward (5′-ACCACGTTGTCACTCAGCAC-3′) ephrin B2 reverse (5′-AGATGTTTGCTGGGCTCTGT-3′), flt4 forward (5′-TCTCGTTAGTGCCGTATCCA-3′), flt4 reverse (5′- GATGATGTGTGCTGGCTGTT-3′), kdr/flt1 forward (5′-CGCGCAACAGGTCACTATT-3′), kdr/flt1 reverse (5′-GTGAGGAGGATGTCGAGGAG-3′), vegfcc forward (5′- AAGAAGCTGGATGAGGAGACG-3′), vegfcc reverse (5′-GAGGTTGACTCCTCGGACAC-3′), vegfab forward (5′-CAGTGTGAGCCTTGCTGTTC-3′), and vegfab reverse (5′- CCATAGGCCTCCTGTCATTT-3′).

2.5. RT--qPCR for miR-30b and miR-30c {#s2e}
-------------------------------------

qPCR of zebrafish mature microRNA (miR) was performed according to the manufacturer\'s instructions using TaqMan MicroRNA Assays. Briefly, total RNA from groups of 30 pooled 48 hpf zebrafish embryos was purified using Trizol. cDNA was prepared using the TaqMan microRNA Reverse Transcription kit (Applied Biosystems) and qPCR performed using TaqMan microRNA Assays for miR-30b and miR-30c (Applied Biosystems). The primers used for RT--qPCR were supplied with each assay. Each is a stem-loop oligonucleotide containing the sequence of the mature miR (miR-30b:UGUAAACAUCCUACACUCAGCU; miR-30c: UGUAAACAUCCUACACUCUCAG).

qPCR was performed in triplicate using a 7900HT Fast Real-Time PCR System (Applied Biosystems). miR-30b and miR-30c expression levels were normalized to mean expression of the control group at 48 hpf.

2.6. Whole mount RNA *in situ* hybridization {#s2f}
--------------------------------------------

Experiments were performed as previously described.^[@CVT170C3]^ Expression was detected with RNA probes labelled with digoxigenin (Roche) and resolved using BM Purple (Roche). *dll4* antisense probe was synthesized from delta-like 4 cDNA fragment (kind gift from Roger Patient, Oxford, UK).

2.7. Live imaging and microscopy {#s2g}
--------------------------------

Embryos were lightly anaesthetized using MS-222 (Tricaine) added to the incubating medium and immobilized in 0.5% low-melting point agarose and mounted in a chamber slide for visualization. Confocal microscopy was performed using an IX81 inverted motorized microscope (Olympus), Ultraview VOX confocal spinning disc imaging system (Perkin Elmer, Waltham, MA, USA). Images were acquired using Velocity software v5.3.2 (Perkin Elmer). Z stack images were acquired in 2 μm slices using sequential laser scanning of the region of interest. All analyses and quantification of vessel parameters were performed using ImageJ (v1.44 public domain software <http://rsbweb.nih.gov/ij/>). Stacks are presented as the maximum intensity Z projections. To quantify aortic Notch signalling in *CSL:venus* transgenics, we quantified fluorescence intensity in a two somite length of the wall of the aorta just above the anus. To quantify the vessel length in *Fli1:GFP* or *kdrl:HRAS-mCherry* transgenics we quantified the entire length of endothelium present in a region spanning two somites (containing three ISVs, and the dorsal longitudinal anastamotic vessel and any aberrant ISV sprouts). To quantify endothelial cell nuclei in *flk1:GFPnls* transgenics we counted the total nuclei in two somites, including the aorta, ISVs, and dorsal longitudinal anastamotic vessel. Stacks were analysed blinded and group sizes are as specified.

2.8. Statistics {#s2h}
---------------

Statistical comparisons were by Student\'s *t*-test for two group comparisons or ANOVA for more than two groups, and were performed using Graphpad Prism software. Group sizes are indicated in the results section. A *P* \< 0.05 was considered statistically significant. Quantitative data are presented as mean ± SEM.

3.. Results {#s3}
===========

3.1. Absence of blood flow leads to up-regulation of endothelial notch signalling {#s3a}
---------------------------------------------------------------------------------

Morpholino antisense knockdown of cardiac-specific troponin T2 (*tnnt2*) has been shown to prevent cardiac contraction during development,^[@CVT170C18]^ although embryos survive for several days with otherwise normal development.^[@CVT170C3]^

To examine whether blood flow alters Notch signalling, we induced morpholino antisense knockdown of *tnnt2* in a transgenic zebrafish line *Tg(CSL:venus)qmc61.* This expresses the YFP derivative Venus driven by concatemerized CSL-binding sites (the DNA-binding site of the CSL transcription factor required for most Notch signalling). In these embryos, Venus is expressed at sites of Notch signalling, notably the neural tube and less strongly in the developing vasculature, and is a useful reporter for Notch signalling. *tnnt2* knockdown prevented cardiac contraction in these embryos at all time points studied up to 5 d post-fertilization (dpf); no erythrocyte movement could be detected in any blood vessel in *tnnt2* morphants, whereas in control morphants brisk blood flow was observed in all vessels.

When we examined venus expression in the vasculature in these transgenic embryos at 72 h post-fertilization (hpf) we observed a statistically significant up-regulation of Notch signalling in the aorta of *tnnt2* morphants. *Figure [1](#CVT170F1){ref-type="fig"}A* shows the vascular anatomy of a zebrafish embryo for orientation; the area of trunk examined in subsequent studies is indicated by a box. *Figure [1](#CVT170F1){ref-type="fig"}B* shows the trunk region of a representative control and *tnnt2* morphant *Tg(CSL:venus)qmc61* transgenic. Reporter expression can be seen in the aorta (arrowhead) and neural tube running dorsally to the aorta in both embryos, but the intensity of aortic expression is greater in the *tnnt2* morphant. We quantified the reporter expression in the aorta in 72 hpf control and *tnnt2* morphants (nine per group) and found a statistically significant increase in aortic fluorescence induced by *tnnt2* knockdown (*P* \< 0.001), shown in *Figure [1](#CVT170F1){ref-type="fig"}D*. We repeated this experiment in 48 hpf embryos and found a similar up-regulation of reporter expression ([Supplementary material online, *Figure S1*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvt170/-/DC1)). These observations suggested that blood flow may suppress CSL-mediated Notch signalling in the vasculature at these developmental stages. Figure 1The absence of blood flow increases endothelial Notch signalling. (*A*) Vascular anatomy of a *Fli1:eGFP* transgenic zebrafish (vascular reporter line) for orientation. Scale bar = 500 μm. A boxed region of trunk indicates site of (*B*) and (*C*). (*B*) 3 dpf *Tg(CSL-venus)qmc61* transgenic embryos with blood flow (control MO) or no blood flow (*tnnt2* MO). Scale bar = 100 µm. Arrowhead indicates dorsal aorta. (*C*) The mean aortic fluorescence in 3 dpf *Tg(CSL-venus)qmc61* embryos control and *tnnt2* morphants. Scale bar = 100 µm. (*D*) 3 dpf *Tg(CSL-venus)qmc61* transgenic embryos with blood flow (vehicle treated) or no blood flow (15 mM BDM treatment) from 36 hpf. ISVs, intersegmental vessels. Scale bar = 100 µm. (*E*) The mean aortic fluorescence in 3 dpf *Tg(CSL-venus)qmc61* embryos in vehicle- and BDM-treated groups.

*tnnt2* knockdown prevents circulation from ever commencing and could have effects other than preventing blood flow. We therefore sought to reproduce these findings using another method and examine whether absent blood flow increases Notch signalling in embryos that have previously experienced blood flow. Incubation of zebrafish embryos in the myosin ATPase inhibitor 2,3-butanedione 2-monoxime (BDM) has been shown to induce reversible cessation of cardiac contraction.^[@CVT170C20]^ We therefore used BDM to stop cardiac contraction in *Tg(CSL:venus)qmc61* zebrafish embryos from 36 hpf (onset of circulation was at 26 hpf) until 72 hpf. Although a brisk normal circulation was established in all embryos at 36hpf, BDM treatment halted cardiac contraction within 15 min, causing complete absence of circulation. As with *tnnt2* knockdown, cessation of cardiac output by BDM led to a significant up-regulation of Venus expression in the aorta (*Figure [1](#CVT170F1){ref-type="fig"}C*). When we quantified this effect, we found that cessation of blood flow led to a statistically significant increase in aortic Notch signalling (*n* = 8/group, *P* \< 0.01) shown in *Figure [1](#CVT170F1){ref-type="fig"}E*). Taken together, these experiments suggest that the absence of blood flow leads to up-regulation of Notch signalling in the vasculature by some mechanism.

3.2. Absence of blood flow leads to up-regulation of endothelial Notch signalling by up-regulation of dll4 {#s3b}
----------------------------------------------------------------------------------------------------------

To determine how blood flow might regulate Notch signalling, we extracted RNA from the trunk of 48 hpf *tnnt2* and control morphants (3 replicate experiments of 30 embryos per group) and performed quantitative rt--PCR for a range of Notch ligands and receptors, VEGF ligands and receptors, and *CXCR4a* (*Figure [2](#CVT170F2){ref-type="fig"}A*). As we previously described, *CXCR4a* was significantly up-regulated by the absence of blood flow (*P* \< 0.05).^[@CVT170C3]^ The Notch ligand *dll4* was also significantly up-regulated in *tnnt2* morphants (*P* \< 0.05). Figure 2The absence of blood flow up-regulates the expression of *dll4* (*A*) Quantitative RT--PCR for Notch ligands and receptors, VEGF ligands and receptors, and *cxcr4a* performed on trunk RNA from 48 hpf control and *tnnt2* morphants. (*B*) Whole mount *in situ* hybridization for *dll4* in 48 hpf control and *tnnt2* morphants. Arrowhead indicates dorsal aorta, ISVs in *tnnt2* morphant arrowed. Scale bar = 100 μm.

To examine spatial localization of the *dll4* expression, we performed whole mount *in situ* hybridization in 48 hpf control and *tnnt2* morphants. This confirmed *dll4* was up-regulated within the aorta and ISVs of *tnnt2* morphants. Representative micrographs are shown in *Figure [2](#CVT170F2){ref-type="fig"}B*; 10 of 10 control morphants had the appearance shown, whereas 12 of 13 *tnnt2* morphants had clear up-regulation of *dll4* as depicted. It should be noted that our *in situ* protocol was optimised to show *dll4* upregulation in the absence of flow; more prolonged staining revealed aortic and ISV expression of *dll4* in embryos with blood flow, but this was substantially less than in embryos without flow).

The above data suggested that the up-regulation of Notch signalling induced by the absence of blood flow in *Figure [1](#CVT170F1){ref-type="fig"}* could be mediated via *dll4* up-regulation. To test this, we co-injected a previously published *dll4* morpholino with or without the *tnnt2* morpholino to knockdown *dll4* in 3 dpf *Tg(CSL:venus)qmc61* embryos with or without blood flow. In the presence of flow *dll4* knockdown did not alter Venus expression in the aorta (*n* = 19) compared with control morphants (*n* = 18). This lack of effect of *dll4* knockdown on reporter expression in embryos with blood flow may be due to insensitivity of the reporter, perdurance or consitutive CSL activity. However, as before, *tnnt2* knockdown induced a significant increase in Notch signalling (*n* = 11, *P* \< 0.001). However, in similar *tnnt2* morphants, *dll4* knockdown was sufficient to prevent the up-regulation of aortic Notch signalling detected by Venus expression induced by *tnnt2* knockdown (*n* = 11). *Figure [3](#CVT170F3){ref-type="fig"}A* shows representative micrographs of the trunk vasculature in control and *tnnt2* morphants with and without *dll4* knockdown. *Figure [3](#CVT170F3){ref-type="fig"}B* shows the quantification of the aortic fluorescence from all the embryos examined. These data confirmed that the absence of blood flow leads to up-regulation of Notch signalling via up-regulation of *dll4* expression. Figure 3*dll4* knockdown blocks the up-regulation of Notch signalling in the absence of blood flow (*A*) The effect of *dll4* knockdown on reporter expression in 3 dpf *Tg(CSL-venus)qmc61* embryos with and without blood flow due to *tnnt2* knockdown. Arrowhead indicates dorsal aorta and arrow indicates an ISV. (*B*) The mean aortic fluorescence in 3 dpf control and *dll4* morphant *Tg(CSL-venus)qmc61* embryos with and without blood flow due to *tnnt2* knockdown. Scale bar = 100 μm.

Our finding that *dll4* was up-regulated in 48 hpf *tnnt2* morphants was surprising, as previous studies reported down-regulation of *dll4* in 36 hpf *tnnt2* morphants (but not 24 hpf) by *in situ* hybridization and qPCR.^[@CVT170C21]^ We therefore extended our experiments to 72 hpf embryos, which continued to show up-regulation of *dll4* in the vessels of *tnnt2* morphants ([Supplementary material online, *Figure S2*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvt170/-/DC1)). This is consistent with the up-regulation of Notch signalling seen at the same developmental stage (*Figure [1](#CVT170F1){ref-type="fig"}*). It appears therefore that although Wang *et al.* showed down-regulation of *dll4* in *tnnt2* morphants at earlier stages of development, this is subsequently followed by up-regulation for at least the following 36 h.

Recent work has shown that the microRNA species miR-30b and miR-30c regulate *dll4*.^[@CVT170C22]^ We therefore questioned whether the effect of blood flow on *dll4* levels is mediated via effects on the expression of this microRNA. We performed qPCR to quantify the expression of both miR-30b and miR-30c in 48 hpf control and *tnnt2* morphant embryos. We found no significant difference in the expression of either miR ([Supplementary material online, *Figure S3*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvt170/-/DC1)), suggesting blood flow does not suppress *dll4* expression via miR-30.

3.3. Absence of blood flow does not affect normal ISV patterning but prevents excessive angiogenesis in vhl mutants with constitutively activated hypoxic signalling {#s3c}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------

*dll4* is expressed by endothelial tip cells during ISV formation, and reduction of *dll4* expression leads to excessive and aberrant ISV angiogenesis.^[@CVT170C23]^ However, despite the absence of blood flow leading to up-regulation of *dll4* expression and Notch signalling, we previously showed this is not associated with abnormal ISV formation in wild-type embryos,^[@CVT170C3]^ which do not experience hypoxia in the absence of blood flow.^[@CVT170C1]^ We therefore asked whether blood flow would be required for angiogenesis driven by up-regulation of hypoxic signalling. Low tissue oxygen levels lead to increased HIF1α signalling, which induces gene expression changes that are highly pro-angiogenic.^[@CVT170C24]^ However, incubation of zebrafish embryos in hypoxia leads to a reduction in cardiac output and blood flow, preventing direct testing of the interactions between low oxygen tension and blood flow during angiogenesis.

We therefore examined vascular development in zebrafish embryos that have constitutively activated HIF1α signalling due to mutation in the von Hippel Lindau (*vhl*) gene.^[@CVT170C14]^ These embryos have previously been shown to exhibit excessive angiogenesis due to up-regulation of VEGF signalling.^[@CVT170C25]^ These mutants therefore represent a powerful model of hypoxic-signalling driven angiogenesis. We crossed *vhl* mutants with existing transgenic lines that allowed visualization of endothelial cells, cytoplasm (*Fli1:GFP*^[@CVT170C15]^), nuclei (*Flk1:GFPnls*^[@CVT170C16]^), or endothelial membrane (*kdrl:HRAS-mCherry*^[@CVT170C17]^).

*Figure [4](#CVT170F4){ref-type="fig"}B--D* show higher power images of the ISVs in a representative wild-type embryo at 3, 4, and 5 dpf. By 3 dpf, the ISV pattern is largely established, with limited remodelling over the subsequent 2 days. *Figure [4](#CVT170F4){ref-type="fig"}E--G* show the same region in a *vhl^−/−^* mutant. As previously described,^[@CVT170C25]^ *vhl^−/−^* mutants exhibited aberrant ISV angiogenesis that became more apparent between 3 and 5 days post-fertilization (dpf). We quantified ISV diameter and compared with wild types (*n* = 5) this was significantly increased in *vhl^−/−^* mutants \[*n* = 5, *P* \< 0.001), *Figure [4](#CVT170F4){ref-type="fig"}H*\]. Similarly, when we quantified ISV length, this was significantly greater in *vhl^−/−^* mutants (*n* = 5, *P* \< 0.001) compared with wild types (*n* = 5). Figure 4*vhl*^−/−^ mutant zebrafish demonstrates excessive angiogenesis of trunk vessels during embryonic development. (*A*) Vascular anatomy of a *Fli:eGFP* wild-type embryo for orientation. Scale bar = 500 μm, regions of (*B*--*G*) boxed. (*B--D*) Mid-trunk intersegmental (ISV) and DLAV vessels from 3 to 5 dpf in a wild-type *Fli:eGFP* transgenic. (*E--G*) Mid-trunk vessels in a *vhl*^−/−^ 3--5 dpf *Fli:eGFP* transgenic. Scale bars for *B--G* = 25 μm. H; ISV diameter of 3 dpf wt and *vhl*^−/−^ at 3 dpf. I: total ISV length in 3 dpf wt and *vhl^−/−^* mutants.

We next examined the effect of preventing cardiac contraction by *tnnt2* knockdown on abnormal ISV formation in *vhl^−/−^* mutants. Representative 3 dpf *Fli1:GFP* wild-type and *vhl^−/−^* mutant transgenics with and without *tnnt2* knockdown are shown in *Figure [5](#CVT170F5){ref-type="fig"}A*. Although as we previously described, *tnnt2* knockdown did not affect ISV patterning in wild-type embryos (aside from a collapsed appearance due to lack of blood flow), the excessive ISV angiogenesis in homozygous *vhl^−/−^* mutants was completely abolished. When we quantified ISV length, we confirmed that *tnnt2* knockdown did not significantly affect this in wild-type embryos (*n* = 5/group), but that *tnnt2* knockdown reduced the increased total vessel length in *vhl^−/−^* mutants to wild-type levels (*P* \< 0.001, *n* = 5--7/group) (*Figure [5](#CVT170F5){ref-type="fig"}B*). Figure 5*tnnt2* knockdown prevents excessive angiogenesis in *vhl^−/−^* zebrafish. (*A*) The mid-trunk vascular anatomy of 3 dpf *Tg(fli:eGFP)* wild type and *vhl^−/−^* with and without blood flow due to *tnnt2* knockdown (site of imaging boxed in *Figure [4](#CVT170F4){ref-type="fig"}A*). (*B*) The total vessel length of 3 dpf wt control morphants, *vhl^−/−^* control morphants, and wt and *vhl^−/−^ tnnt2* morphants. (*C*) Endothelial nuclei in 3 dpf *flk1:EGFP-nls* wt and *vhl^−/−^* injected with *tnnt2* or control morpholino. (*D*) The effect of *tnnt2* knockdown on number of endothelial nuclei in a two-somite region of the mid trunk in 3 dpf wild type and *vhl^−/−^*.

The *Flk1:GFPnls* transgenic labels endothelial nuclei, allowing quantification of endothelial cell number. We therefore examined the effect of prevention of blood flow by *tnnt2* knockdown on endothelial cell number in 3 dpf wild-type and *vhl^−/−^* mutant embryos. Representative 3 dpf *Flk1:GFPnls* wild-type and *vhl^−/−^* mutant transgenics with and without *tnnt2* knockdown are shown in *Figure [5](#CVT170F5){ref-type="fig"}C*. When we quantified endothelial cell number, we found that compared with wild-type embryos with normal blood flow (*n* = 20), *tnnt2* knockdown (*n* = 8) did not significantly affect endothelial cell number in a two-somite region of the mid trunk. As might be expected from the excessive vessel formation seen in *Fli1:GFP vhl^−/−^* mutants shown in *Figure [4](#CVT170F4){ref-type="fig"}E--G*, in the presence of blood flow *vhl^−/−^* mutants (*n* = 11), had a significantly greater number of endothelial cells (*P* \< 0.001) compared with wild-types (*Figure [5](#CVT170F5){ref-type="fig"}D*). However, prevention of blood flow in *vhl^−/−^* mutants by *tnnt2* knockdown (*n* = 11) reduced this to wild-type levels (*P* \< 0.001), confirming that blood flow is required for the excessive angiogenesis in *vhl^−/−^* mutants.

To confirm that the effect of *tnnt2* knockdown on angiogenesis in *vhl^−/−^* mutants could be seen by preventing blood flow using an alternative method, we exposed wild-type and *vhl^−/−^* mutant embryos to BDM from 36 hpf until 72 hpf. We performed these experiments using a double transgenic (*flk1:EGFP-nls* labelling endothelial nuclei with GFP and *kdrl:HRAS-mCherry* labelling endothelial membrane with mCherry), allowing simultaneous quantification of vessel length and endothelial cell number. *Figure [6](#CVT170F6){ref-type="fig"}A* shows representative 3 dpf wild-type and *vhl^−/−^* double transgenics with and without BDM treatment. In control-treated *vhl^−/−^* mutants with blood flow, excessive endothelial cell number and ISV sprouting is apparent, whereas BDM treatment significantly reduced both vessel length (*Figure [6](#CVT170F6){ref-type="fig"}B*, *P* \< 0.001) and endothelial cell number (*Figure [6](#CVT170F6){ref-type="fig"}C*, *P* \< 0.001) to wild-type levels (*n* = 11/group). The data confirmed that the absence of blood flow prevented the excess ISV angiogenesis in *vhl^−/−^* mutants, though preserving normal ISV architecture and endothelial cell number. Figure 6Pharmacological inhibition of blood flow blocks excessive angiogenesis in *vhl^−/−^* mutant zebrafish. (*A*) 3 dpf Tg(*kdrl:memRFP*; *flk1:EGFP-nls)* double transgenic wild type or *vhl^−/−^* mutants, treated with vehicle or \[15 mM\] BDM to stop blood flow from 36 hpf until 3 dpf (site of imaging boxed in *A*). (*B*) A total vessel length at 3 dpf of wt, *vhl^−/−^*, and BDM-treated groups. (*C*) The mean number of endothelial nuclei in a two-somite mid-trunk region in wt and *vhl^−/−^* treated with BDM or vehicle.

4.. Discussion {#s4}
==============

Most studies of angiogenesis use *in vitro* models that seldom reproduce the exposure to blood flow. The contribution of blood flow to vascular development has been little studied, perhaps because angiogenesis clearly can proceed in the absence of blood flow *in vitro* and in several *in vivo* contexts, such as those that precede cardiac output.

However, recent studies have revealed that the contribution of blood flow to angiogenesis is highly complex and context-dependent. Dependent upon the model and vessel studied, published reports have shown blood flow to be required,^[@CVT170C5],[@CVT170C7]^ dispensable,^[@CVT170C3]^ or inhibitory^[@CVT170C8],[@CVT170C9]^ for vessel formation. This uncertainty led us to investigate potential mechanisms for integration of blood flow with angiogenic pathways. The zebrafish is an attractive model for this purpose due to its proven ability to oxygenate via diffusion even when cardiac contraction is entirely halted,^[@CVT170C1]^ at least in the first several days of development.

The Notch pathway is a complex and fundamental mechanism in embryonic development and disease. Although Notch signalling is required for vascular development,^[@CVT170C11]^ including lymphatic development,^[@CVT170C19]^ it can also play an inhibitory role in angiogenesis, by repressing tip cell formation.^[@CVT170C13],[@CVT170C26]^ The regulation of this multifaceted contribution to vascular development is likely to be multi-layered. However, we find that the Notch ligand *dll4* is clearly transcriptionally repressed by blood flow in the aorta and ISVs of 48 h post-fertilization zebrafish embryos. This provides a potential pathway for blood flow to integrate with other signals to modulate angiogenesis. Although Notch ligand/receptor interactions lead to signalling in both ligand and receptor bearing cells, this does not appear to affect angiogenesis in the ligand-bearing cell.^[@CVT170C27]^ This suggests that any modulation of angiogenesis induced by flow mediated alteration in *dll4* expression is likely to be mediated by effects on Notch receptor-expressing cells, rather than in an autocrine fashion.

The previous work by Wang *et al.*^[@CVT170C21]^ found that the absence of blood flow led to a decrease in *dll4* expression at 36 hpf. Our finding that at later time points the same manipulation leads to increased *dll4* expression is supported by a number of lines of evidence. Wang *et al*. did not examine whether *tnnt2* knockdown led to alteration in Notch signalling, whereas we found this is indeed up-regulated by the absence of blood flow. We also confirmed that a second method of halting circulation (incubation in the drug BDM) induced up-regulation of Notch signalling at the same time points used for *tnnt2* knockdown studies. Our findings do not contradict Wang *et al.*, since they studied earlier stages of development. It is possible that *tnnt2* knockdown does reduce *dll4* expression at 38 hpf, but this is followed by the up-regulation we demonstrate at later time points. The reason for such a biphasic response is unclear, but the data from our Notch reporter studies up to 72 hpf strongly suggest that the overall effect of absent blood flow is an increase, not a decrease, in vascular Notch signalling.

The exact mechanism whereby the physical forces of blood flow influence the expression of *dll4* remains unclear. Although several transcription factors (notably *klf2*) have been demonstrated to mediate the transcription of hundreds of genes in response to shear stress, recent work has highlighted the potential for microRNAs to similarly influence gene expression in response to haemodynamic alteration.^[@CVT170C5]^ Nicoli *et al.* showed that blood flow induces klf2a which in turn up-regulates miR-126. However, recent work suggests miR-126 increases, rather than decreases *dll4* expression,^[@CVT170C28]^ suggesting miR-126 is not the mechanism whereby blood flow suppresses *dll4*.

We examined one candidate, miR-30 which regulates *dll4* expression in other circumstances,^[@CVT170C22]^ but found no evidence to suggest this particular miR is the link between blood flow and *dll4*. Although target prediction algorithms suggest miR-30 is the microRNA species most likely to target *dll4*, this does not exclude the possibility that other miRs regulate *dll4* under conditions of altered haemodynamic forces. The up-regulation of hypoxic signalling in *vhl* mutants would be predicted to up-regulate so-called hypoxamirs^[@CVT170C29]^ such as miR-210,^[@CVT170C30]^ which are highly likely to underlie the angiogenic phenotype and these may also integrate blood flow with angiogenic signalling. Such a link would be interesting to explore in future work.

Despite our finding that blood flow regulates Notch signalling, this is insufficient in itself to alter ISV formation during normal angiogenic development, since ISVs form normally, with normal endothelial cell number, even in the complete absence of blood flow. We therefore sought to identify whether other forms of angiogenesis might be more sensitive to alterations in blood flow.

Up-regulation of hypoxic signalling induces a profoundly pro-angiogenic response, and unsurprisingly constitutive activation of this process by homozygous mutation of *vhl* induces excessive angiogenesis in the ISVs of developing zebrafish embryos. We show for the first time that angiogenesis promoted by this up-regulation of hypoxic signalling is prevented in the absence of blood flow. Although a recent study has suggested that a reduction in cardiac output may induce hypoxic signalling in zebrafish, this occurred after 7 dpf,^[@CVT170C31]^ significantly later than the 3--5 dpf embryos examined in our work. Even if reducing blood flow induced hypoxia, this would be predicted to increase, not decrease the angiogenic response.

We are unable to say for certain how cessation of blood flow exerts its effect on Notch signalling and aberrant angiogenesis in *vhl* mutants. Various stimuli will occur in response to either preventing or halting blood flow in the vasculature, as we achieved in our models. Even if oxygenation is maintained, it is possible that CO~2~, being a larger, less diffusible molecule may have accumulated in the tissue. Since teleosts have been shown to possess carbonic anhydrase,^[@CVT170C32]^ an accumulation of CO~2~ could lead to increased osmotically active HCO~3~^−^ which themselves may induce alterations in physical forces exerted on the vasculature. However, we believe that the effects of blood flow on Notch signalling and angiogenesis seen in our study are more likely to be exerted via mechanotransduction of the physical forces exerted by blood flow, rather than biochemically.

*vhl^−/−^* mutants experience increased levels of cardiac output and blood flow,^[@CVT170C14]^ and this must be considered in interpreting our results. It is possible that increased levels of blood flow might suppress Notch signalling still further than in wild types, and this would be predicted to lead to increased angiogenesis. However, as VEGF inhibition reduces angiogenesis in *vhl* mutants, it seems likely the abnormal angiogenesis seen in these mutants is predominantly driven by hypoxic signalling, rather than by increased blood flow. Nevertheless, our data suggest that blood flow and hypoxic signalling integrate at some level to permit angiogenesis.

Our work has several limitations. Most notably, we have been unsuccessful in demonstrating whether the requirement for blood flow in hypoxic-signalling driven angiogenesis is mediated by suppression of Notch signalling. Notch inhibition in *vhl* mutants without blood flow, either by morpholino knockdown of *dll4* or pharmacological inhibition with gamma secretase inhibitors leads to embryonic death, which has prevented us from testing the hypothesis that Notch inhibition might rescue the excessive angiogenesis in *vhl* mutants even in the absence of blood flow. Exposing embryos directly to hypoxia reduces blood flow. This prevented us from examining the interaction of blood flow with angiogenesis stimulated by low oxygen tension (true hypoxia) as opposed to angiogenesis driven by up-regulated hypoxic signalling in normoxic conditions as in the *vhl* mutant. Nevertheless, the twin observations that blood flow suppresses Notch signalling via the repression of *dll4* expression, and that blood flow is required for angiogenesis driven by hypoxic signalling, both add to our understanding of how blood flow may contribute to angiogenesis, and underline that mechanisms of angiogenesis differ according to context.

Our data suggest that targeting mechanosensory pathways that sense blood flow might prevent angiogenesis in situations where this is driven by hypoxia. This could potentially open novel therapeutic strategies for conditions such as diabetic retinopathy where ischaemia stimulates the neoangiogenesis that leads to visual impairment.^[@CVT170C33]^ In addition, since Notch inhibition may sensitize some tumours to chemotherapy,^[@CVT170C34]^ an ability to down-regulate Notch by exposure to fluid forces or blood flow might have adjuvant benefits for cancer therapeutics. As VEGF drives much of the angiogenic reponse to hypoxia, a requirement for blood flow for angiogenesis to occur in response to VEGF could underlie the disappointing clinical results of VEGF treatment for coronary artery disease^[@CVT170C35]^ as it may not have induced neovascularization when delivered to poorly perfused tissues. Further study of the interactions between blood flow and angiogenesis seems likely to reveal further intricacies of the regulation of vascular formation in development and disease.
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